A method for the prevention, treatment, or amelioration of a medical disease or condition associated with inflammation caused by glutamate excitotoxicity comprising administering to a patient a peptide that binds to or interferes with the P38 MAPK-COX2-PGE.sub.2 and ERK MAPK-CX3CL1-sCX3CL1 pathways.

The technology described herein is directed to engineered chemoautotrophic bacteria and methods of producing sustainable biomolecules. In several aspects, described herein are engineered bacteria and corresponding methods, compositions, and systems for the production of products such as polyhydroxyalkanoates (PHA), sugar feedstocks, and lipochitooligosaccharide (LCO) fertilizers.

The technology described herein is directed to engineered chemoautotrophic bacteria and methods of producing sustainable biomolecules. In several aspects, described herein are engineered bacteria and corresponding methods, compositions, and systems for the production of products such as polyhydroxyalkanoates (PHA), sugar feedstocks, and lipochitooligosaccharide (LCO) fertilizers.

An O-phosphoserine (OPS) export protein variant, and a method for producing O-phosphoserine, cysteine, and cysteine derivatives using the same.

An O-phosphoserine (OPS) export protein variant, and a method for producing O-phosphoserine, cysteine, and cysteine derivatives using the same.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor and/or survival factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes a survival factor, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor and/or a different survival factor.

Disclosed are compositions and methods for directing proteins to specific loci in the genome and uses thereof. In one aspect, the disclosed methods allow for directing proteins to specific loci in the genome of an organism, including the steps of providing a fusion protein comprising a DNA localization component and an effector molecule. Preferred embodiments of the disclosure include, but are not limited to, the following fusion proteins: dSaCas9-Clo051, dCas9-Clo051, Xanthomonas-TALE-Clo051, and Ralstonia-TALE-Clo051.

Disclosed are compositions and methods for directing proteins to specific loci in the genome and uses thereof. In one aspect, the disclosed methods allow for directing proteins to specific loci in the genome of an organism, including the steps of providing a fusion protein comprising a DNA localization component and an effector molecule. Preferred embodiments of the disclosure include, but are not limited to, the following fusion proteins: dSaCas9-Clo051, dCas9-Clo051, Xanthomonas-TALE-Clo051, and Ralstonia-TALE-Clo051.

Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems, using truncated guide RNAs (tru-gRNAs).

Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems, using truncated guide RNAs (tru-gRNAs).